Question 1

What are the most cited papers from Moberg Pharma (Sweden)?

Accepted Answer

The most cited paper from Moberg Pharma (Sweden) is "A phase II, randomized, double‐blind, placebo‐controlled, dose‐ranging study to evaluate the efficacy and safety of VT‐1161 oral tablets in the treatment of patients with distal and lateral subungual onychomycosis of the toenail*" (Boni Elizabeth Elewski et al., 2020), with 42 citations. Next come "Treatment of distal subungual onychomycosis with a topical preparation of urea, propylene glycol and lactic acid: results of a 24‐week, double‐blind, placebo‐controlled study" (30) and "Treatment of seborrhoeic dermatitis of the scalp with a topical solution of urea, lactic acid, and propylene glycol (K301): results of two double‐blind, randomised, placebo‐controlled studies" (30).

Question 2

Which research topics does Moberg Pharma (Sweden) publish most on?

Accepted Answer

By volume in 2022-now: Clostridium difficile and Clostridium perfringens research, Nail Diseases and Treatments, Antibiotic Use and Resistance and Nosocomial Infections in ICU.

Question 3

Which fields of science does Moberg Pharma (Sweden) work in?

Accepted Answer

In all years, 56% of research at Moberg Pharma (Sweden) is in Health Sciences, 22% in Social Sciences. Its largest fields are Medicine (56%), Social Sciences (22%), Biochemistry, Genetics and Molecular Biology (13%). It does 1.4× the world's share of Health Sciences.

Question 4

Is Moberg Pharma (Sweden)'s research output growing?

Accepted Answer

Output in 2022-2025 was 40% lower than in 2018-2021.